Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage

NCT ID: NCT00314756

Last Updated: 2023-08-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-03-31
• Study Completion Date: 2005-11-30

Brief Summary

To assess the efficacy of treating a nodular basal cell carcinoma with imiquimod cream after initial treatment with curettage

Detailed Description

The primary objective of this study is to evaluate the efficacy of imiquimod 5% cream on nodular BCC lesions treated 5x/week for 6 weeks after primary treatment with curettage without electrodesiccation. The secondary objective of this study is to evaluate the cosmetic outcome after treatment of the lesions using this modality.

Conditions

Basal Cell Carcinoma

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

imiquimod

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Are willing and able to give informed consent;

2. Are at least 18 years of age;

3. Are willing to comply with all study requirements, evaluations, and procedures

4. Have 1 clinically typical, visible nodular BCC lesion which meets the following criteria:

• a primary lesion (not recurrent, not previously treated or biopsied)
• non-infected
• size between 0.25 and 1.5 cm2
• located at least 1 cm from the eyes, nose, mouth, ear, and hairline to exclude the H-zone of the face
• clinically consistent with nodular BCC
• histologically consistent with nodular BCC and have no histological evidence of a morpheaform or micronodular pattern
• suitable for treatment with surgical excision
• easily identifiable and treatable by subject or reliable subject representative

5. Are free of any significant physical abnormalities or previous scarring in the potential application site area that may cause difficulty with examinations.

6. Are willing to stop using over-the-counter retinol products or products containing alpha or beta hydroxyacids in the treatment and surrounding area 8 hours prior to treatment with the imiquimod cream and clinic visits.

Exclusion Criteria

1. Have evidence of clinically significant, unstable, cardiovascular or immunosuppressive, hematologic, hepatic, neurologic, renal, endocrine, collagen-vascular, or gastrointestinal abnormalities or disease that may interfere with completion of the study.

2. Have any dermatological disease in the treatment or surrounding area that may be exacerbated by treatment with imiquimod or cause difficulty with examination.

3. Have a BCC lesion located within 1 cm of the eyes, nose, mouth, ear, and hairline.

4. Are pregnant at the screening or treatment initiation visit.

5. Have known allergies to any excipient in the study cream

6. Have undergone any surgical procedures in the potential treatment area within 4 weeks of the screening/treatment initiation visit. In addition, skin in the potential application area must be healed.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Wake Forest University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Phillip M Williford, MD

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Medical Center

Locations

Wake Forest University Medical Center

Winston-Salem, North Carolina, United States

Countries

United States

Other Identifiers

BG04-484

Identifier Type: -

Identifier Source: org_study_id